Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Pfizer Japan, Takeda to Copromote Tofacitinib in Japan
February 14, 2011
- FDA Not to Approve AcipHex Extended-Release Capsules
February 14, 2011
- MSD Recalls Intron
February 14, 2011
- 4 General Test Methods Harmonized
February 14, 2011
- Nitto Denko Acquires Avecia Biotechnology
February 14, 2011
- Korosho to Consider Relief System for Deaths Due to Anticancer Drugs
February 14, 2011
- Operating Profits of Top 6 Wholesalers Near Worst-Ever Levels
February 14, 2011
- Korosho to Collect ADR Reports Directly from Patients
February 14, 2011
- Drugstore Chain Operators Continue Point Services Despite JACDS Call
February 14, 2011
- Korosho's Study Group Exchanges Opinions on Safety Info. Diffusion System
February 14, 2011
- Astellas, Kaketsuken Tie Up to Market Encevac
February 7, 2011
- Gilenya Receives Positive Opinion from CHMP: Novartis
February 7, 2011
- JSMI to Propose Tax Break for All OTC Drugs
February 7, 2011
- AnGes MG to Raise ¥300 Mil. from Shionogi to Develop NF-κB Oligo
February 7, 2011
- GRU to Target Online Sales of OTC Drugs, Basic Dispensing Fees
February 7, 2011
- Shionogi to Recall Class 3 OTC Drugs
February 7, 2011
- MTPC Terminates Joint Development of Roflumilast with Nycomed
February 7, 2011
- Present Industry's Opinions to Office of Medical Innovation: Mr Kawakami
February 7, 2011
- Sunovion Aims at Rapid Market Entry for Latuda by Replacing Existing Products
February 7, 2011
- Hayashibara Applies for Business Revitalization ADR
February 7, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…